Financial Contrast: PTC Therapeutics (NASDAQ:PTCT) and Zealand Pharma A/S (OTCMKTS:ZLDPF)

Zealand Pharma A/S (OTCMKTS:ZLDPF) and PTC Therapeutics (NASDAQ:PTCT) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, institutional ownership and analyst recommendations.

Earnings & Valuation

This table compares Zealand Pharma A/S and PTC Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zealand Pharma A/S	$1.40 billion	2.20	$977.29 million	$6.03	7.13
PTC Therapeutics	$1.01 billion	5.41	$682.64 million	($0.58)	-112.71

Zealand Pharma A/S has higher revenue and earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Zealand Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Zealand Pharma A/S has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500.

Profitability

This table compares Zealand Pharma A/S and PTC Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zealand Pharma A/S	58.86%	18.53%	17.14%
PTC Therapeutics	-3.80%	-362.45%	-1.32%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Zealand Pharma A/S and PTC Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zealand Pharma A/S	0	9	1	1	2.27
PTC Therapeutics	2	2	10	1	2.67

PTC Therapeutics has a consensus price target of $98.50, indicating a potential upside of 50.68%. Given PTC Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe PTC Therapeutics is more favorable than Zealand Pharma A/S.

Summary

Zealand Pharma A/S beats PTC Therapeutics on 8 of the 12 factors compared between the two stocks.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

About PTC Therapeutics

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.